Provention bio resubmitting biologics license application for delay of clinical type 1 diabetes in at-risk individuals following type b meeting with the fda

Red bank, n.j., jan. 27, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubmit the teplizumab biologics license application (bla) for the delay of clinical type 1 diabetes in at-risk individuals following its type b pre-bla resubmission meeting with the u.s. food and drug administration (fda).
PRVB Ratings Summary
PRVB Quant Ranking